March 2021 Special Edition
Volume 7, Issue 4.1
This supplement discusses new immunotherapies for myeloma, the role of transplant in treating patients with peripheral T-cell lymphomas, and more.
Table of Contents
March 2021 Special Edition
Charting the Myeloma Immunotherapy Landscape
A bevy of forthcoming immunotherapies for multiple myeloma over the next few years raises hopes, as well as questions about combinations, sequencing, and potential...
Use of Transplant Persists as Appropriate Option in PTCLs
Backed by experience, but not randomized data, most institutions have established practices for transplant in patients with peripheral T-cell lymphomas.
No consensus exists on the...
March 2021 Special Edition
Predicting CAR T-Cell Treatment Failure in Patients With Aggressive B-Cell Lymphomas
Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse...
Moving Beyond Gene Rearrangements to Define High-Risk Diffuse Large B-Cell Lymphoma
In diffuse large B-cell lymphoma (DLBCL), patients typically are risk-stratified according to cell-of-origin, but recent genetics-based classifications led the World Health Organization to establish...
March 2021 Special Edition
Researchers Validate Burkitt Lymphoma Prognostic Index
Researchers have created a prognostic index specific to Burkitt lymphoma (BL) that will allow for simplified stratification and comparison of risk distribution in geographically...
Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL
Thiotepa-containing conditioning regimens, including thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU), were associated with favorable survival outcomes in patients with primary diffuse large B-cell lymphoma of...
Durable Efficacy With LOXO-305 in Heavily Pretreated CLL/SLL
LOXO-305, a highly selective noncovalent Bruton tyrosine kinase (BTK) inhibitor, was associated with promising response and efficacy rates in patients with heavily pretreated and...
Idecabtagene Vicleucel Promising in Pretreated Myeloma
Three-quarters of patients with heavily pretreated multiple myeloma responded to treatment with the B-cell maturation antigen (BCMA)−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene...
Evaluating Iberdomide Plus Daratumumab or Bortezomib in Relapsed/Refractory Myeloma
Triplet combinations consisting of iberdomide, a cereblon E3 ligase immunomodulatory drug, with dexamethasone and daratumumab (IberDd) or bortezomib and dexamethasone (IberVd) demonstrated favorable tolerability...
